CD274 and non-small cell lung carcinoma: Variability among PD-L1 scoring was evaluated in all patient samples by first evaluating our novel TI 22C3 NSCLC DA compared to pathologist’s manual evaluation of PD-L1 scoring in a digital-to-manual assessment.